FDA Approves Altuviiio: Sanofi's Long-Acting Hemophilia A Therapy

The U.S. Food and Drug Administration (FDA) has granted approval to Altuviiio, an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein, developed by Sanofi, marking a significant advancement in the treatment of Hemophilia A. This FDA Altuviiio approval introduces a novel long-acting recombinant factor VIII therapy designed to improve the management of bleeding episodes in patients with this coagulation disorder.

Drug Overview

Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein) is a recombinant factor VIII replacement therapy and an Fc fusion protein. It is indicated for the treatment of Hemophilia A. The drug works by combining recombinant antihemophilic factor VIII with an Fc domain to engage the neonatal Fc receptor (FcRn) recycling pathway, a von Willebrand factor (VWF) binding domain to enhance stability, and XTEN polypeptides to increase molecular size and reduce renal clearance, collectively extending the half-life of factor VIII.

Clinical Insights

Altuviiio's approval is supported by Phase III clinical trials that demonstrated its efficacy in preventing and controlling bleeding episodes in patients with Hemophilia A. The primary endpoint was the annualized bleeding rate (ABR). The trials showed that Altuviiio effectively manages bleeding events. Safety data from the trials indicate that class-typical adverse events include infusion site reactions, development of factor VIII inhibitors (neutralizing antibodies), hypersensitivity reactions, and rare thromboembolic events.

Regulatory Context

The FDA approval for Altuviiio follows a Biologics License Application (BLA) submission. [Source: U.S. Food and Drug Administration] The application included data from Phase I-III clinical trials demonstrating safety, efficacy, and pharmacokinetics. The FDA's review process included an evaluation of manufacturing processes, immunogenicity, and post-marketing surveillance plans. The approval reflects the unmet need for longer-acting factor VIII products to improve the quality of life for Hemophilia A patients.

Market Impact

In the U.S., the Hemophilia A treatment market includes approximately 20,000 individuals, a subset of whom are eligible for prophylactic factor replacement. Altuviiio will compete with existing extended half-life factor VIII products, addressing the need for longer-acting therapies. By offering improved dosing convenience and treatment adherence, Altuviiio has the potential to capture a significant share of the market by offering improved dosing convenience and treatment adherence.

Future Outlook

Future developments for Altuviiio may include label expansions to cover additional patient populations or indications. Post-marketing studies will continue to monitor the drug's long-term safety and efficacy. There may also be potential combination trials to explore synergistic effects with other therapies.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-05.